OncoSil Medical
Caner Turay is a seasoned marketing professional currently serving as the Director of Marketing at OncoSil Medical since June 2022. Prior to this role, Caner held various positions at Boston Scientific from January 2020 to June 2022, including Senior Product Manager for Radioembolization in the EMEA region and Market Development Manager. Caner also gained valuable experience at BTG plc from October 2014 to January 2020, where roles included Country Sales Manager for Turkey & the Middle East and Account Manager. Earlier experience includes positions at Eczacıbaşı-Monrol Nuclear Products from April 2010 to September 2014, and a brief tenure as Product Manager at Mikro-Gen in late 2009. Caner's career began as a Sales & Marketing Representative at Hemakim Tıbbi Ürünler San. ve Tic. A.Ş. from February 2007 to July 2008. Caner holds a degree from Boğaziçi University (2000-2006) and further education from Istanbul Bilgi University (2006-2008).
This person is not in any teams
This person is not in any offices
OncoSil Medical
OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.